RAS inhibition by angiotensin-converting enzyme inhibitors (ACEi), which inhibits the conversion of AngI to AngII, or angiotensin receptors blockers (ARBs) decreases proteinuria in patients with diabetic nephropathy and halts the disease progression to ESRD, thus improving patient survival (82). The gene discussed is ACE; the disease is diabetic kidney disease.